Bioqube Ventures is a global life sciences investment firm with offices in Belgium and the United States. The firm focuses on companies developing first- or best-in-class therapeutics to address major unmet medical needs. Bioqube builds balanced portfolios and supports companies from inception through early clinical milestones. For more information, please visit www.bioqubeventures.com Bioqube Ventures is dedicated to funding therapeutic innovations: - A life sciences venture capital fund – dedicated to advancing exciting science in European and US ecosystems to breakthrough therapies for patients. - A fit-for-purpose dual investment model – besides more classical investments in investment rounds, we have special attention for venture creation projects that require additional experiments prior to creating new ventures. With our in-house factory model we are able to translate exciting science into trailblazing companies. - A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths. We believe in putting our expertise at work where it matters.
Looking for a particular Bioqube Ventures employee's phone or email?
The Bioqube Ventures annual revenue was $5 million in 2026.
Nico Vandervelpen is the Co-founder and Managing Partner of Bioqube Ventures.
15 people are employed at Bioqube Ventures.
Bioqube Ventures is based in Brussels, Brussels.
The NAICS codes for Bioqube Ventures are [523920, 523, 52392, 5239, 52].
The SIC codes for Bioqube Ventures are [628, 62].